Morgan Stanley upgraded Alvotech (ALVO) to Overweight from Equal Weight with a $14 price target The firm says the company’s “consistent” research and commercial progress provide visibility on its outlook and validation of its operating model. Alvotech’s “breadth” of commercial partners across geographies is a value driver for the shares, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO: